EN
中文 EN
Investor Relations
Why Invest in CanSinoBIO
Corporate Governance
Stock Information
Information Disclosure
Sustainability
Investor Relations Contact
Why Invest in CanSinoBIO
Bio-tech To Bio-pharma
  • • From a biotechnology company to a biopharmaceutical company
  • • Continuously R&D investing, Aligning with positive progress of core pipelines
  • • BD Possibilities: licensing in & out, M&As and overseas partnership in pipelines
World Class R&D
  • • Senior scientists and management team from leading global biopharmaceutical companies
  • • Mature technology platforms with patents awarded & articles published in world-leading medical journals The Lancet, Nature etc.
  • • Competitive advantages in mRNA technology platform and process of CMC associated
  • • With the mRNA platform is streamlined
International Manufacturing Standard
  • • Core technical experts with in-depth understanding of international production standards and requirements
  • • Design, construction & operation of production facilities meets international standards
  • • Large-scale modern vaccine industrial bases in Tianjin and Shanghai
Growing Commercialization Capability
  • • Well-oiled commercialization engine with systematic management approach of a multi-national company
  • • Unique Direct Sales and Sales Agency Model for growing market penetration, with commercial access to 30 provinces in China
  • • Large potential overseas market with multiple strategic partnership
Stock Information
H股CanSinoBIO（06185）
30.000
Data synchronization time 2024-12-02 16:08:06
More
A股CanSinoBIO（688185）
67.990
Data synchronization time 2024-12-02 15:00:01
More
Information Disclosure
A Share H Share
Sustainability
Overview
ESG Report
Investor Relations Contact
To provide innovative, high-quality and affordable vaccine
Address:
401-420, 4th Floor, Biomedical Park, 185 South Avenue, TEDA West District, Tianjin, PRC
Hong Kong:
Room 1901, 19/F, Lee Garden One, 33 Hysan Avenue, Causeway Bay Hong Kong
Tel:
022-58213766
Email:
ir@cansinotech.com